iPierian (formerly iZumi Bio) was a South San Francisco biopharmaceutical company founded in 2008 that pioneered the use of induced pluripotent stem cell (iPSC) technology to model and develop therapies for neurodegenerative diseases, including ALS and tauopathies. The company was acquired by Bristol-Myers Squibb in 2014 for up to $725 million.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account